Beatrice (psychedelic)

Beatrice (psychedelic)

Beatrice (psychedelic)

Beatrice, also known as 2C-B, is a psychedelic drug of the 2C family. It was first synthesized by Alexander Shulgin in 1974. In Shulgin's book PiHKAL, the dosage range is listed as 12–24 mg. As a psychedelic, 2C-B is classified as a Schedule II drug under the Convention on Psychotropic Substances.

History

Beatrice was first synthesized and studied by Alexander Shulgin, a renowned chemist and psychopharmacologist. Shulgin's work in the field of psychedelic research led to the discovery and synthesis of many novel substances, including the 2C family of drugs.

Pharmacology

Beatrice acts primarily as a serotonin receptor agonist. It has a high affinity for the 5-HT2A receptor, which is thought to be the primary target of psychedelic drugs. The drug also has some affinity for the 5-HT2C receptor.

Effects

The effects of Beatrice are often described as a cross between the effects of LSD and MDMA. Users report visual effects, enhanced tactile sensation, and altered perception of time and space. The effects typically last for 4–8 hours.

Legal Status

Beatrice is classified as a Schedule II drug under the Convention on Psychotropic Substances, indicating that it has a high potential for abuse and has no accepted medical use.

See Also

• 2C-I
• 2C-E
• 2C-T-7
• Psychedelic therapy

References

This psychedelic-related article is a stub. You can help WikiMD by expanding it.